Managed Access Programs for INC424, Ruxolitinib

Conditions

• Primary Myelofibrosis (PMF)
• Post Polycythemia Myelofibrosis (PPV MF)
• Thrombocythemia Myelofibrosis (PET-MF)
• Severe/Very Severe COVID-19 Illness
• Polycythemia Vera (PV)
• Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)
• Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Interventions

• DRUG: Ruxolitinib

Sponsor

Novartis Pharmaceuticals